AMAmanda de Oliveira Maurílio

Amanda de Oliveira Maurílio

*This is an algorithmically generated author record based on publicly available information.

Amanda de Oliveira Maurílio has a total of 204 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction: Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients

    by Flávio de Azevedo Figueiredo, Lucas Emanuel Ferreira Ramos, Rafael Tavares Silva, Daniela Ponce, Rafael Lima Rodrigues de Carvalho, Alexandre Vargas Schwarzbold, Amanda de Oliveira Maurílio, Ana Luiza Bahia Alves Scotton, Andresa Fontoura Garbini, Bárbara Lopes Farace, et al.

  • Open Access

    Potential and limitations of machine meta-learning (ensemble) methods for predicting COVID-19 mortality in a large inhospital Brazilian dataset

    by Bruno Barbosa Miranda de Paiva, Polianna Delfino Pereira, Claudio Moisés Valiense de Andrade, Virginia Mara Reis Gomes, Maira Viana Rego Souza-Silva, Karina Paula Medeiros Prado Martins, Thaís Lorenna Souza Sales, Rafael Lima Rodrigues de Carvalho, Magda Carvalho Pires, Lucas Emanuel Ferreira Ramos, et al.

    The majority of early prediction scores and methods to predict COVID-19 mortality are bound by methodological flaws and technological limitations (e.g., the use of a single prediction model). Our aim is to provide a thorough comparative study that tackles those methodological issues, considering multiple techniques to build mortality prediction models, including modern machine learning (neural) algorithms and traditional statistical techniques, as well as meta-learning (ensemble) approaches. This study used a dataset from a multicenter cohort of 10,897 adult Brazilian COVID-19 patients, admitted from March/2020 to November/2021, including patients [median age 60 (interquartile range 48–71), 46% women]. We also proposed new original population-based meta-features that have not been devised in the literature. Stacking has shown to achieve the best results reported in the literature for the death prediction task, improving over previous state-of-the-art by more than 46% in Recall for predicting death, with AUROC 0.826 and MacroF1 of 65.4%. The newly proposed meta-features were highly discriminative of death, but fell short in producing large improvements in final prediction performance, demonstrating that we are possibly on the limits of the prediction capabilities that can be achieved with the current set of ML techniques and (meta-)features. Finally, we investigated how the trained models perform on different hospitals, showing that there are indeed large differences in classifier performance between different hospitals, further making the case that errors are produced by factors that cannot be modeled with the current predictors.


  • Open Access

    Clinical characteristics and outcomes of hospital-manifested COVID-19 among Brazilians

    by Polianna Delfino-Pereira, Magda Carvalho Pires, Virginia Mara Reis Gomes, Matheus Carvalho Alves Nogueira, Maria Clara Pontello Barbosa Lima, Alexandre Vargas Schwarzbold, Amanda de Oliveira Maurílio, Ana Luiza Bahia Alves Scotton, André Soares de Moura Costa, Barbara Lopes Farace, et al.


  • Open Access

    Lesão Miocárdica e Prognóstico em Pacientes Hospitalizados com COVID-19 no Brasil: Resultados do Registro Nacional de COVID-19

    by Hannah Cardoso Barbosa, Maria Auxiliadora Parreiras Martins, Jordana Cristina de Jesus, Karina Cardoso Meira, Luiz Guilherme Passaglia, Manuela Furtado Sacioto, Adriana Falangola Benjamin Bezerra, Alexandre Vargas Schwarzbold, Amanda de Oliveira Maurílio, Barbara Lopes Farace, et al.

    Resumo Fundamento As complicações cardiovasculares da COVID-19 são aspectos importantes da patogênese e do prognóstico da doença. Evidências do papel prognóstico da troponina e da lesão miocárdica em pacientes hospitalizados com COVID-19 na América Latina são ainda escassos. Objetivos Avaliar a lesão miocárdica como preditor independente de mortalidade hospitalar e suporte ventilatório mecânico em pacientes hospitalizados, do registro brasileiro de COVID-19. Métodos Este estudo coorte é um subestudo do registro brasileiro de COVID-19, conduzido em 31 hospitais brasileiros de 17 [...] Resumo Fundamento As complicações cardiovasculares da COVID-19 são aspectos importantes da patogênese e do prognóstico da doença. Evidências do papel prognóstico da troponina e da lesão miocárdica em pacientes hospitalizados com COVID-19 na América Latina são ainda escassos. Objetivos Avaliar a lesão miocárdica como preditor independente de mortalidade hospitalar e suporte ventilatório mecânico em pacientes hospitalizados, do registro brasileiro de COVID-19. Métodos Este estudo coorte é um subestudo do registro brasileiro de COVID-19, conduzido em 31 hospitais brasileiros de 17


  • Frequency and burden of neurological manifestations upon hospital presentation in COVID-19 patients: Findings from a large Brazilian cohort

    by Milena Soriano Marcolino, Fernando Anschau, Luciane Kopittke, Magda Carvalho Pires, Izabela Guimarães Barbosa, Daniella Nunes Pereira, Lucas Emanuel Ferreira Ramos, Luís Fernando Israel Assunção, André Soares de Moura Costa, Matheus Carvalho Alves Nogueira, et al.


  • Hospital characteristics associated with COVID-19 mortality: data from the multicenter cohort Brazilian Registry

    by Maira Viana Rego Souza-Silva, Patricia Klarmann Ziegelmann, Vandack Nobre, Virginia Mara Reis Gomes, Ana Paula Beck da Silva Etges, Alexandre Vargas Schwarzbold, Aline Gabrielle Sousa Nunes, Amanda de Oliveira Maurílio, Ana Luiza Bahia Alves Scotton, André Soares de Moura Costa, et al.

    The COVID-19 pandemic caused unprecedented pressure over health care systems worldwide. Hospital-level data that may influence the prognosis in COVID-19 patients still needs to be better investigated. Therefore, this study analyzed regional socioeconomic, hospital, and intensive care units (ICU) characteristics associated with in-hospital mortality in COVID-19 patients admitted to Brazilian institutions. This multicenter retrospective cohort study is part of the Brazilian COVID-19 Registry. We enrolled patients ≥ 18 years old with laboratory-confirmed COVID-19 admitted to the participating hospitals from March to September 2020. Patients’ data were obtained through hospital records. Hospitals’ data were collected through forms filled in loco and through open national databases. Generalized linear mixed models with logit link function were used for pooling mortality and to assess the association between hospital characteristics and mortality estimates. We built two models, one tested general hospital characteristics while the other tested ICU characteristics. All analyses were adjusted for the proportion of high-risk patients at admission. Thirty-one hospitals were included. The mean number of beds was 320.4 ± 186.6. These hospitals had eligible 6556 COVID-19 admissions during the study period. Estimated in-hospital mortality ranged from 9.0 to 48.0%. The first model included all 31 hospitals and showed that a private source of funding (β = − 0.37; 95% CI − 0.71 to − 0.04; p = 0.029) and location in areas with a high gross domestic product (GDP) per capita (β = − 0.40; 95% CI − 0.72 to − 0.08; p = 0.014) were independently associated with a lower mortality. The second model included 23 hospitals and showed that hospitals with an ICU work shift composed of more than 50% of intensivists (β = − 0.59; 95% CI − 0.98 to − 0.20; p = 0.003) had lower mortality while hospitals with a higher proportion of less experienced medical professionals had higher mortality (β = 0.40; 95% CI 0.11–0.68; p = 0.006). The impact of those association increased according to the proportion of high-risk patients at admission. In-hospital mortality varied significantly among Brazilian hospitals. Private-funded hospitals and those located in municipalities with a high GDP had a lower mortality. When analyzing ICU-specific characteristics, hospitals with more experienced ICU teams had a reduced mortality.


  • Open Access

    Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients

    by Flávio de Azevedo Figueiredo, Lucas Emanuel Ferreira Ramos, Rafael Tavares Silva, Daniela Ponce, Rafael Lima Rodrigues de Carvalho, Alexandre Vargas Schwarzbold, Amanda de Oliveira Maurílio, Ana Luiza Bahia Alves Scotton, Andresa Fontoura Garbini, Bárbara Lopes Farace, et al.

    Background: Acute kidney injury (AKI) is frequently associated with COVID-19, and the need for kidney replacement therapy (KRT) is considered an indicator of disease severity. This study aimed to develop a prognostic score for predicting the need for KRT in hospitalised COVID-19 patients, and to assess the incidence of AKI and KRT requirement. Methods: This study is part of a multicentre cohort, the Brazilian COVID-19 Registry. A total of 5212 adult COVID-19 patients were included between March/2020 and September/2020. Variable selection was performed using generalised additive models (GAM), and least absolute shrinkage and selection operator (LASSO) regression was used for score derivation. Accuracy was assessed using the area under the receiver operating characteristic curve (AUC-ROC). Results: The median age of the model-derivation cohort was 59 (IQR 47–70) years, 54.5% were men, 34.3% required ICU admission, 20.9% evolved with AKI, 9.3% required KRT, and 15.1% died during hospitalisation. The temporal validation cohort had similar age, sex, ICU admission, AKI, required KRT distribution and in-hospital mortality. The geographic validation cohort had similar age and sex; however, this cohort had higher rates of ICU admission, AKI, need for KRT and in-hospital mortality. Four predictors of the need for KRT were identified using GAM: need for mechanical ventilation, male sex, higher creatinine at hospital presentation and diabetes. The MMCD score had excellent discrimination in derivation (AUROC 0.929, 95% CI 0.918–0.939) and validation (temporal AUROC 0.927, 95% CI 0.911–0.941; geographic AUROC 0.819, 95% CI 0.792–0.845) cohorts and good overall performance (Brier score: 0.057, 0.056 and 0.122, respectively). The score is implemented in a freely available online risk calculator (https://www.mmcdscore.com/). Conclusions: The use of the MMCD score to predict the need for KRT may assist healthcare workers in identifying hospitalised COVID-19 patients who may require more intensive monitoring, and can be useful for resource allocation.


  • Open Access

    Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients

    by Flávio de Azevedo Figueiredo, Lucas Emanuel Ferreira Ramos, Rafael Tavares Silva, Magda Carvalho Pires, Daniela Ponce, Rafael Lima Rodrigues de Carvalho, Alexandre Vargas Schwarzbold, Amanda de Oliveira Maurílio, Ana Luiza Bahia Alves Scotton, Andresa Fontoura Garbini, et al.

    Background: Acute kidney injury (AKI) is frequently associated with COVID-19 and the need for kidney replacement therapy (KRT) is considered an indicator of disease severity. This study aimed to develop a prognostic score for predicting the need for KRT in hospitalized COVID-19 patients. Methods: This study is part of the multicentre cohort, the Brazilian COVID-19 Registry. A total of 5,212 adult COVID-19 patients were included between March/2020 and September/2020. We evaluated four categories of predictor variables: (1) demographic data; (2) comorbidities and conditions at admission; (3) laboratory exams within 24 h; and (4) the need for mechanical ventilation at any time during hospitalization. Variable selection was performed using generalized additive models (GAM) and least absolute shrinkage and selection operator (LASSO) regression was used for score derivation. The accuracy was assessed using the area under the receiver operating characteristic curve (AUC-ROC). Risk groups were proposed based on predicted probabilities: non-high (up to 14.9%), high (15.0 – 49.9%), and very high risk (≥ 50.0%). Results: The median age of the model-derivation cohort was 59 (IQR 47-70) years, 54.5% were men, 34.3% required ICU admission, 20.9% evolved with AKI, 9.3% required KRT, and 15.1% died during hospitalization. The validation cohort had similar age, sex, ICU admission, AKI, required KRT distribution and in-hospital mortality. Thirty-two variables were tested and four important predictors of the need for KRT during hospitalization were identified using GAM: need for mechanical ventilation, male gender, higher creatinine at admission, and diabetes. The MMCD score had excellent discrimination in derivation (AUROC = 0.929; 95% CI 0.918–0.939) and validation (AUROC = 0.927; 95% CI 0.911–0.941) cohorts an good overall performance in both cohorts (Brier score: 0.057 and 0.056, respectively). The score is implemented in a freely available online risk calculator ( https://www.mmcdscore.com/ ). Conclusion: The use of the MMCD score to predict the need for KRT may assist healthcare workers in identifying hospitalized COVID-19 patients who may require more intensive monitoring, and can be useful for resource allocation.

  • Open Access

    Frequency and burden of neurological manifestations in hospitalized patients with COVID-19: findings from a large Brazilian cohort

    by Milena Soriano Marcolino, Fernando Anschau, Luciane Kopittke, Magda Carvalho Pires, Izabela Guimarães Barbosa, Daniella Nunes Pereira, Renata Brant de Souza Melo, Luís Fernando Israel Assunção, André Soares de Moura Costa, Matheus Carvalho Alves Nogueira, et al.

    Background Scientific data regarding the prevalence of COVID-19 neurological manifestations and prognosis in Latin America countries is still lacking. Therefore, the study aims to understand neurological manifestations of SARS-CoV 2 infection in the Brazilian population and its association with patient outcomes, such as in-hospital mortality. Methods This study is part of the Brazilian COVID-19 Registry, a multicentric COVID-19 cohort, including data from 37 Brazilian hospitals. For the analysis, patients were grouped according to the presence of self-reported vs. clinically-diagnosed neurological manifestations and matched with patients without neurological manifestations by age, sex, number of comorbidities, hospital, and whether or not patients ha neurological underlying disease. Results From 7,232 hospitalized patients with COVID-19, 27.8% presented self-reported neurological manifestations, 9.9% were diagnosed with a clinically-defined neurological syndrome and 1.2% did not show any neurological symptoms. In patients with self-reported symptoms, the most common ones were headache (19.3%), ageusia (10.4%) and anosmia (7.4%). Meanwhile, in the group with clinically-defined neurological syndromes, acute encephalopathy was the most common diagnosis (10.5%), followed by coma (0.6%1) and seizures (0.4%). Men and younger patients were more likely to self-report neurological symptoms, while women and older patients were more likely to develop a neurological syndrome. Patients with clinically-defined neurological syndromes presented a higher prevalence of comorbidities, as well as lower oxygen saturation and blood pressure at hospital admission. In the paired analysis, it was observed that patients with clinically-defined neurological syndromes were more likely to require ICU admission (46.9 vs. 37.9%), mechanical ventilation (33.4 vs. 28.2%), to develop acute heart failure (5.1 vs. 3.0%, p=0.037) and to die (40.7 vs. 32.3%, p<0.001) when compared to controls. Conclusion Neurological manifestations are an important cause of morbidity in COVID-19 patients. More specifically, patients with clinically defined neurological syndromes presented a poorer prognosis for the disease when compared to matched controls.

  • Open Access

    Hospital-Manifested SARS-CoV-2 Infection in Brazil: Clinical Characteristics, Outcomes and Risk Factors for Mortality

    by Polianna Delfino Pereira, Magda Carvalho Pires, Virginia Mara Reis Gomes, Matheus Carvalho Alves Nogueira, Maria Clara Pontello Barbosa Lima, Alexandre Vargas Schwarzbold, Amanda de Oliveira Maurílio, Ana Luiza Bahia Alves Scotton, André Soares de Moura Costa, Bárbara Lopes Farace, et al.

    Background: Some patients manifest COVID-19 symptoms while admitted for other reasons. Thus, we aimed to analyze clinical characteristics and outcomes of patients who developed COVID-19 symptoms during hospitalization when compared to those of patients hospitalized due to COVID-19; and to evaluate the risk factors related to mortality in the first population. Methods: This retrospective study included adult COVID-19 patients, hospitalized between March/2020 and September/2020. Demographic data, clinical characteristics and outcomes were extracted from medical records. Patients who manifested in-hospital COVID-19 (study group) and those who were admitted due to COVID-19 (control group) were matched by propensity score model. Logistic regression models were used to verify the risk factors for mortality, in the study group. Findings: Among 7,710 patients, 7·2% developed COVID-19 symptoms while admitted for other reasons. The most common causes of hospitalization were cardiovascular diseases (20·0%), and propaedeutics (19·5). The study group had a higher prevalence of alcoholism (8·8% vs. 2·8%), chronic renal disease (3·5% vs. 1·7%), and cancer (19·2% vs. 10·8%) when compared to controls (p<0·05 for all), as well as a higher rate of intensive care unit requirement (45·1% vs. 35·2%), sepsis (23·8% vs 14·5%), and death (35·8% vs. 22·5%), respectively (p<0·05 for all). The factors independently associated with increased mortality in the study group were increasing age, male sex, number of comorbidities and cancer. Interpretation: COVID-19 in-hospital manifestation was associated with worse outcomes. Older age, male sex, number of comorbidities, and cancer were independent risk factors for mortality. Funding Information: This study was supported in part by Minas Gerais State Agency for Research and Development (Fundação de Amparo à Pesquisa do Estado de Minas Gerais - FAPEMIG) [grant number APQ-01154-21], National Institute of Science and Technology for Health Technology Assessment (Instituto de Avaliação de Tecnologias em Saúde – IATS)/ National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq) [grant number 465518/2014-1], and CAPES Foundation (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) [grant number 88887.507149/2020-00]. Declaration of Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Ethics Approval Statement: The study protocol was approved by the National Commission for Research Ethics (CAAE: 30350820.5.1001.0008).